These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

248 related articles for article (PubMed ID: 33624165)

  • 21. [Mechanisms and therapeutics of glucocorticoid-induced osteoporosis].
    Kaneko K; Kawai S
    Nihon Rinsho Meneki Gakkai Kaishi; 2011; 34(3):138-48. PubMed ID: 21720102
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Secondary osteoporosis or secondary contributors to bone loss in fracture. Therapeutic strategy for glucocorticoid-induced osteoporosis].
    Hayakawa N; Suzuki A
    Clin Calcium; 2013 Sep; 23(9):1337-44. PubMed ID: 23999371
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Efficacy of intravenous alendronate for the treatment of glucocorticoid-induced osteoporosis in children with autoimmune diseases.
    Inoue Y; Shimojo N; Suzuki S; Arima T; Tomiita M; Minagawa M; Kohno Y
    Clin Rheumatol; 2008 Jul; 27(7):909-12. PubMed ID: 18330609
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Efficacy and safety of 18 anti-osteoporotic drugs in the treatment of patients with osteoporosis caused by glucocorticoid: A network meta-analysis of randomized controlled trials.
    Liu Z; Zhang M; Shen Z; Ke J; Zhang D; Yin F
    PLoS One; 2020; 15(12):e0243851. PubMed ID: 33326444
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Clinical efficacy of denosumab, teriparatide, and oral bisphosphonates in the prevention of glucocorticoid-induced osteoporosis: a systematic review and meta-analysis.
    Yuan C; Liang Y; Zhu K; Xie W
    J Orthop Surg Res; 2023 Jun; 18(1):447. PubMed ID: 37349750
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The clinical utility of TRACP-5b to monitor anti-resorptive treatments of osteoporosis.
    Gossiel F; Ugur A; Peel NFA; Walsh JS; Eastell R
    Osteoporos Int; 2022 Jun; 33(6):1357-1363. PubMed ID: 35102444
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Alendronate prevents glucocorticoid-induced osteoporosis in patients with rheumatic diseases: A meta-analysis.
    Kan SL; Yuan ZF; Li Y; Ai J; Xu H; Sun JC; Feng SQ
    Medicine (Baltimore); 2016 Jun; 95(25):e3990. PubMed ID: 27336902
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Prevalence and incidence of osteoporotic fractures in patients on long-term glucocorticoid treatment for rheumatic diseases: the Glucocorticoid Induced OsTeoporosis TOol (GIOTTO) study.
    Rossini M; Viapiana O; Vitiello M; Malavolta N; La Montagna G; Maddali Bongi S; Di Munno O; Nuti R; Manzini CU; Ferri C; Bogliolo L; Mathieu A; Cantatore F; Del Puente A; Muratore M; Grassi W; Frediani B; Saviola G; Delvino P; Mirone L; Ferraccioli G; Tripi G; Piazza I; Gatti D
    Reumatismo; 2017 May; 69(1):30-39. PubMed ID: 28535619
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Serum bone alkaline phosphatase is a useful marker to evaluate lumbar bone mineral density in Japanese postmenopausal osteoporotic women during denosumab treatment.
    Nakamura Y; Suzuki T; Kato H
    Ther Clin Risk Manag; 2017; 13():1343-1348. PubMed ID: 29062234
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Comparison of denosumab and oral bisphosphonates for the treatment of glucocorticoid-induced osteoporosis: a systematic review and meta-analysis.
    Jiang L; Dong J; Wei J; Liu L
    BMC Musculoskelet Disord; 2022 Nov; 23(1):1027. PubMed ID: 36447169
    [TBL] [Abstract][Full Text] [Related]  

  • 31. High fracture risk patients with glucocorticoid-induced osteoporosis should get an anabolic treatment first.
    Lespessailles E; Chapurlat R
    Osteoporos Int; 2020 Oct; 31(10):1829-1834. PubMed ID: 32780152
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Once-weekly oral alendronate 70 mg in patients with glucocorticoid-induced bone loss: a 12-month randomized, placebo-controlled clinical trial.
    Stoch SA; Saag KG; Greenwald M; Sebba AI; Cohen S; Verbruggen N; Giezek H; West J; Schnitzer TJ
    J Rheumatol; 2009 Aug; 36(8):1705-14. PubMed ID: 19487264
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Denosumab versus alendronate in long-term glucocorticoid users: A 12-month randomized controlled trial.
    Mok CC; Ho LY; Leung SMT; Cheung HN; Chen SPL; Ma KM
    Bone; 2021 May; 146():115902. PubMed ID: 33631355
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Comparison of Bisphosphonates Versus Teriparatide in Therapy of the Glucocorticoid-Induced Osteoporosis (GIOP): A Meta-Analysis of Randomized Controlled Trials.
    Dong B; Zhou Y; Wang J; Li C; Fu Z; Huang Y; Wang Y; Xu L
    Horm Metab Res; 2023 Apr; 55(4):236-244. PubMed ID: 36652960
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Denosumab in the treatment of glucocorticoid-induced osteoporosis.
    Coskun Benlidayi I
    Rheumatol Int; 2018 Nov; 38(11):1975-1984. PubMed ID: 30019224
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Efficacy of discontinuing risedronate for patients with systemic lupus erythematosus: a prospective study.
    Ishida T; Yoshida S; Kimura Y; Fujiki Y; Kotani T; Takeuchi T; Makino S; Arawaka S
    Lupus; 2018 Sep; 27(10):1636-1643. PubMed ID: 29954283
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Comparison of the efficacy of denosumab and bisphosphonates for treating secondary osteoporosis in patients with rheumatoid arthritis.
    Kinoshita H; Miyakoshi N; Kashiwagura T; Kasukawa Y; Sugimura Y; Shimada Y
    Mod Rheumatol; 2017 Jul; 27(4):582-586. PubMed ID: 27659808
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Meta-analysis of the effects of denosumab and romosozumab on bone mineral density and turnover markers in patients with osteoporosis.
    Hu M; Zhang Y; Guo J; Guo C; Yang X; Ma X; Xu H; Xiang S
    Front Endocrinol (Lausanne); 2023; 14():1188969. PubMed ID: 37529613
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The impact of switching once-weekly teriparatide to denosumab in osteoporosis patients.
    Miyagi M; Fujimaki H; Naruse K; Suto K; Inoue G; Nakazawa T; Imura T; Saito W; Uchida K; Shirasawa E; Takahira N; Takaso M
    J Orthop Sci; 2019 Jan; 24(1):153-158. PubMed ID: 30146385
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Effects of Denosumab and Bisphosphonates on Glucocorticoid-induced Osteoporosis in Patients with Neuroimmunological Disorders.
    Handa H; Uzawa A; Mori M; Yasuda M; Onishi Y; Akamine H; Ogaya E; Niibe Y; Yokota H; Kuwabara S
    Intern Med; 2024 Jul; ():. PubMed ID: 38987183
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.